Scroll to top

News Releases

Home
Investors

News Releases

Month Year

Month Year

Investor Alerts

Jul 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August
Jul 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
Jun 22, 2020

Immunic, Inc. to Join Russell 3000® Index
Jun 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Jun 9, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock
Jun 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Show per page